Why Are Indian Drugmakers Racing to Develop Keytruda Biosimilars?
About the Development
India's leading pharmaceutical companies are preparing for one of the biggest opportunities in the global oncology market. Biocon, Zydus Lifesciences and Dr. Reddy's Laboratories are advancing plans to launch biosimilar versions of Keytruda (pembrolizumab), one of the world's best-selling cancer therapies, after patent protection expires across major international markets.
Keytruda generated approximately US$31.7 billion in global sales during 2025, making it one of the largest pharmaceutical products globally. Patent expiry could open a multi-billion-dollar biosimilar opportunity for qualified manufacturers.
As patents expire, biosimilar manufacturers typically seek regulatory approvals to introduce lower-cost alternatives. Successful launches could expand patient access while creating significant revenue opportunities for pharmaceutical companies with strong biologics capabilities.
Key Highlights
🔹 Indian pharmaceutical companies are preparing Keytruda biosimilars.
🔹 Keytruda recorded approximately US$31.7 billion in global sales during 2025.
🔹 Patent protection is expected to expire across key international markets.
🔹 Biocon, Zydus Lifesciences and Dr. Reddy's are among the major participants.
🔹 Biosimilars could significantly reduce treatment costs for eligible patients.
🔹 Oncology remains one of the fastest-growing pharmaceutical segments globally.
🔹 Regulatory approvals and manufacturing capabilities will determine commercial success.
Investors following healthcare opportunities may also explore broader market trends through Nifty Tip insights.
Potential Beneficiaries
| Company | Potential Opportunity |
|---|---|
| Biocon | Expanding biosimilar portfolio and oncology presence. |
| Zydus Lifesciences | Potential entry into high-value oncology biologics. |
| Dr. Reddy's Laboratories | Opportunity to strengthen global biosimilar franchise. |
The eventual commercial opportunity will depend on patent timelines, regulatory approvals, manufacturing readiness and competitive dynamics across different countries.
Strengths & Weaknesses
|
Strengths
🔹 Massive global oncology market. 🔹 Strong Indian biosimilar expertise. 🔹 Potential export growth. 🔹 Lower-cost treatment alternatives. |
Weaknesses
🔹 Complex regulatory approvals. 🔹 High development costs. 🔹 Manufacturing challenges. 🔹 Intense global competition. |
Biosimilar development is significantly more complex than conventional generic medicines, requiring extensive clinical evidence and advanced manufacturing standards before commercial launch.
Opportunities & Threats
|
Opportunities
🔹 Patent expiry opens a large addressable market. 🔹 Rising global demand for affordable cancer treatment. 🔹 Expansion of India's biologics manufacturing capabilities. 🔹 Long-term export potential. |
Threats
🔹 Regulatory delays. 🔹 Patent litigation. 🔹 Price competition after launch. 🔹 Technological execution risks. |
Investors should monitor patent expiry schedules, regulatory filings and commercial launch timelines, as these milestones are likely to determine the pace of revenue generation for participating companies.
Valuation & Investment View
The Keytruda biosimilar opportunity represents a potentially significant long-term growth driver for India's leading biosimilar manufacturers. However, commercial success will depend on timely regulatory approvals, manufacturing scale and the ability to compete effectively in global oncology markets.
Investors may also follow BankNifty Tip updates for broader market developments.
Investor Takeaway
Derivative Pro & Nifty Expert Gulshan Khera, CFP®, observes that blockbuster drug patent expiries often create multi-year opportunities for established biosimilar manufacturers. Investors should monitor regulatory approvals, product launch timelines and execution capabilities before assessing the long-term earnings impact on participating pharmaceutical companies. Read more market insights at Indian-Share-Tips.com.
Related Queries on Keytruda and Biosimilars
🔹 Why is Keytruda important for Indian drugmakers?
🔹 What is a biosimilar medicine?
🔹 Which Indian companies are developing Keytruda biosimilars?
🔹 When will Keytruda patents expire in major markets?
🔹 How could biosimilars affect pharmaceutical company earnings?
SEBI Disclaimer: This article is for educational and informational purposes only and should not be construed as investment advice. Investors should consult their financial advisor before making investment decisions.
